How to Interpret Your Quantiferon Test Results

A QuantiFERON test measures how your immune cells respond to proteins specific to the tuberculosis bacterium, and the result is reported as positive, negative, or indeterminate. Each of those categories sounds simple, but the reality behind the number on your lab report is more layered than a straightforward yes-or-no. The test has a single cutoff value, yet your result’s distance from that cutoff, your health status, and even how the blood sample was handled all shape what the result actually means for you.

What the Test Is Actually Measuring

The current version of the test, called QuantiFERON-TB Gold Plus (QFT-Plus), draws your blood into several tubes. Two of those tubes contain synthetic proteins that mimic parts of the TB bacterium. When your blood sits with those proteins at body temperature, any immune cells that have previously encountered TB will release a signaling molecule called interferon-gamma. The lab measures how much of that molecule appears. If the concentration rises above 0.35 IU/ml compared to a baseline “nil” tube (which contains nothing), the result is reported as positive.

The two antigen tubes are labeled TB1 and TB2, and they do slightly different things. TB1 is designed to trigger one arm of the immune response, while TB2 is built to activate a broader response that includes a second type of immune cell. Research has confirmed this distinction: TB1 primarily triggers CD4 T-cells, while TB2 activates both CD4 and CD8 T-cells, with the CD8 response in TB2 being especially associated with active TB disease rather than latent infection.¹ Testing with specific immune cell clones has directly demonstrated that CD8 T-cells respond to the TB2 tube with dramatically higher interferon-gamma production compared to TB1.²

There is also a “mitogen” tube, which contains a substance that should activate your immune cells regardless of whether you have TB. This tube serves as a quality check: if it does not produce a strong response, your immune system may not be working well enough for the test to be meaningful.

Reading a Positive Result

A positive result means your immune cells recognized TB proteins and produced interferon-gamma above the 0.35 IU/ml threshold. This tells you that at some point, your body encountered TB bacteria. It does not tell you whether the infection is latent (dormant and not contagious) or active (causing disease right now). Your doctor will use symptoms, chest imaging, and sometimes sputum tests to make that distinction.

Not all positive results carry equal weight. A result of 0.40 IU/ml sits barely above the cutoff and has a meaningful chance of flipping to negative on a retest. A result of 10 IU/ml or higher represents a much more robust immune memory. One study following close TB contacts found that those with an initial result of 10 IU/ml or above had roughly six times the risk of developing active TB compared to those with lower positive values.³ So while the lab report says “positive” at any value above 0.35, the magnitude of the number matters clinically.

Comparing the TB1 and TB2 tubes can offer an additional clue. In a study comparing patients with active TB to those with latent infection, the active TB group showed a substantially larger difference between TB2 and TB1 interferon-gamma levels, reflecting greater CD8 T-cell involvement.⁴ This is not yet used as a standalone diagnostic tool, but it is an area of active research.

Reading a Negative Result

A negative result means the interferon-gamma response to both TB1 and TB2 tubes stayed below 0.35 IU/ml, and the mitogen control tube worked properly. In most situations, this is reassuring: your immune system does not appear to recognize TB proteins.

However, a negative result is not a guarantee. False negatives happen, and certain factors raise that risk. A systematic review and meta-analysis found that advanced age and low lymphocyte counts were the most consistently identified risk factors for false-negative results, roughly doubling the odds in each case.⁵ A large European study confirmed age as a significant predictor: for every additional year of age, the odds of a false-negative result ticked up slightly, and this was the only factor that remained significant in their multivariate analysis.⁶

Timing also matters. If you were recently exposed to someone with active TB, your immune system needs time to mount a detectable response. Research suggests the optimal time to retest after a known exposure is roughly ten weeks.⁷ Testing too early after exposure can produce a false negative simply because your body has not had time to build immune memory. An older study pegged this “window period” at about two months, finding that the test and the tuberculin skin test correlated better once that window had passed.⁸

What an Indeterminate Result Means

An indeterminate result is neither positive nor negative. It means the test could not be interpreted, usually for one of two reasons. The most common is that the mitogen (positive control) tube failed to produce an adequate response, which suggests your immune system was not functioning well enough on the day of the test. In a large study of over 4,500 tests, about one in ten came back indeterminate, and in the vast majority of those cases the cause was a low mitogen response. Factors strongly linked to indeterminate results included severe COVID-19, immunosuppressive medications, severe lymphopenia, anemia, and hospitalization.⁹

The second, less common cause is a high nil value, meaning the baseline tube that should show minimal immune activity is instead flooded with interferon-gamma. One study of over 10,000 tests found that about 2% were indeterminate overall, and of those, roughly 40% were due to a high nil response rather than a low mitogen.¹⁰ Some of those patients tested positive for autoimmune markers like rheumatoid factor or antinuclear antibodies, and a much higher proportion had a prior positive test result, suggesting background immune activation rather than immunosuppression. These are two fundamentally different problems producing the same “indeterminate” label on your report, so understanding the mechanism behind your indeterminate result can help guide next steps.

If you receive an indeterminate result, the usual recommendation is to repeat the test once your clinical situation improves, or to consider an alternative test like the T-SPOT.TB, which uses a different laboratory method that can sometimes succeed where the QuantiFERON failed.

The Borderline Zone

The binary cutoff of 0.35 IU/ml can create false confidence in results that land close to it. Researchers have proposed a “borderline zone” spanning roughly 0.20 to 0.99 IU/ml to flag results that deserve extra scrutiny. Test variability in this range has been documented at roughly 0.26 to 0.7 IU/ml, meaning a result of 0.50 could easily measure 0.20 or 0.80 if you drew blood again the next day.¹¹

This variability is not just theoretical. A study examining borderline QFT-Plus results found that when patients with an initial borderline result were retested, more than a third came back convincingly negative, and none of those individuals developed active TB within two years of follow-up.¹² But borderline results are not simply noise. In another study of TB contacts, those with borderline QFT results were much more likely to also test positive on a tuberculin skin test or T-SPOT compared to those with clearly negative results, suggesting that many borderline results reflect genuine, if weak, immune recognition of TB.¹³

If your result falls in this borderline zone, retesting after a few weeks is a reasonable approach. A result that remains positive on retest is more likely to represent true infection, while one that drops below the cutoff may have been statistical noise.

Conversions, Reversions, and Serial Testing

If you undergo periodic testing, such as annual screening for a healthcare job, you may encounter a “conversion” (a switch from negative to positive) or a “reversion” (positive to negative). These shifts are surprisingly common and do not always mean what they seem. A large systematic review and meta-analysis estimated that about 7% of people convert and about 23% revert on repeat testing. Strikingly, nearly half of conversions and about a fifth of reversions were transient, meaning the result flipped back again on a subsequent test.¹⁴

Reversions are especially common in people whose initial positive result was only modestly above the cutoff. In a study of TB household contacts in India, reversions occurred almost exclusively in individuals whose baseline interferon-gamma levels were between 0.35 and 3.0 IU/ml, while those above 3.0 virtually never reverted.¹⁵ Many experts believe that low-level reversions around the cutoff reflect test variability rather than true immunological change. This is why some guidelines suggest using a more stringent threshold for defining conversion, such as requiring the result to rise above 0.70 IU/ml rather than merely crossing 0.35.

How It Compares to the Tuberculin Skin Test

The biggest practical advantage of the QuantiFERON over the older tuberculin skin test (TST) is its specificity in people who have received the BCG vaccine, which is given routinely in much of the world. The TST uses a mix of proteins found in many mycobacterial species, including the BCG vaccine strain, so it frequently gives false positives in vaccinated individuals. The QuantiFERON uses proteins specific to the TB bacterium itself and is not affected by prior BCG vaccination.¹⁶

The clinical impact of this difference is substantial. In a large population-based cohort study in eastern China, where BCG vaccination is nearly universal, agreement between the two tests was poor among vaccinated individuals. BCG vaccination was significantly associated with being TST-positive but QFT-negative, while the QuantiFERON-positive results tracked much more closely with actual TB risk: people who were QFT-positive were over six times more likely to progress to active TB than those who were negative on both tests.¹⁷ In immigrant populations with high BCG coverage, the skin test produced two to three times more positive results than the QuantiFERON at common cutoffs, with the excess likely driven by vaccine and environmental exposures rather than true TB infection.¹⁸

The QuantiFERON also appears to be a better predictor of who will actually develop TB disease. In a prospective cohort of close contacts, untreated individuals with a positive QuantiFERON had a progression rate of about 15%, compared to roughly 2% among untreated skin-test-positive individuals.¹⁹ A follow-up study found that all contacts who progressed to active TB over several years had been QFT-positive, with a progression rate of about 13% among untreated positives and a significantly higher rate in children.²⁰

Results in Children

There has long been concern that immune-based tests perform poorly in young children, whose immune systems are still developing. The evidence is actually more reassuring than many clinicians expect. A multicenter study found that QuantiFERON sensitivity against culture-confirmed TB was about 94% in children under two, 100% in children ages two to five, and 94% in older children, all significantly higher than the 81% observed in adults in the same study. The rate of indeterminate results was also lower in children than in adults.²¹

That said, infants under one year old are a notable exception. A Chinese study found that the youngest children produced lower interferon-gamma responses to both the mitogen and TB antigen tubes, and the sensitivity dropped meaningfully with a higher indeterminate rate in this group.²² For infants, a negative result alone should not rule out TB if clinical suspicion is present.

Results in People Living with HIV

HIV attacks the very immune cells the QuantiFERON test relies on, so the test’s performance is linked to how advanced the HIV infection is. In patients with pulmonary TB, the QuantiFERON was less sensitive in those with HIV (about 65%) than in those without (about 81%), primarily because HIV-positive patients had more indeterminate results. Once indeterminate results were excluded, sensitivity was comparable between the two groups at roughly 83% and 88%, respectively.²³ The critical threshold appears to be a CD4 count of around 300: below that, sensitivity dropped sharply in HIV-positive patients. People with very low CD4 counts, below 100, had about four times the risk of an indeterminate result compared to those with higher counts.²⁴

Pregnancy may also suppress the interferon-gamma response. A study of over 800 pregnant women in Ethiopia found that HIV-positive pregnant women produced substantially lower interferon-gamma levels and had a much higher proportion of borderline results compared to HIV-negative pregnant women. The authors suggested that a lower cutoff might be appropriate for HIV-positive pregnant women to avoid missing infections.²⁵

Results While on Immunosuppressive Therapy

If you take biologic drugs for conditions like psoriasis, rheumatoid arthritis, or inflammatory bowel disease, you are typically screened for TB before starting therapy because these medications can reactivate latent infections. But interpreting the QuantiFERON in this context is tricky. Biologic therapy itself can cause results to fluctuate. In one cohort of psoriasis patients on long-term biologics, positive results appeared and disappeared over time without clear explanation, and in some patients, results shifted from positive to negative and back during active treatment.²⁶

Over an eleven-year follow-up of nearly 200 psoriasis patients on biologics, about 5% converted from negative to positive, but only one of those patients was ultimately diagnosed with active TB.²⁷ This illustrates a recurring theme: a new positive result during immunosuppressive therapy needs clinical evaluation, but it does not automatically mean you have developed TB. Annual retesting is generally recommended for patients on biologics, precisely because the test can fluctuate and because the consequences of missing a reactivation are serious.

When a Positive Result Might Be Wrong

The QuantiFERON is designed to avoid cross-reactivity with BCG and most environmental bacteria, and in general it succeeds. A study in Northern California found that among patients with confirmed nontuberculous mycobacterial (NTM) infections, the test’s specificity was about 94% after excluding those with plausible risk factors for actual latent TB.²⁸ Rare exceptions exist. There is at least one documented case of a false-positive QuantiFERON result linked to infection with Mycobacterium gordonae, an environmental species.²⁹ These cases are uncommon, but they underscore the importance of clinical context when a positive result occurs in someone with no obvious TB exposure.

How Sample Handling Affects Your Results

One factor entirely outside your body can quietly distort QuantiFERON results: what happens to the blood tubes between the draw and the lab. The test requires incubation at body temperature within a specific window. When incubation was delayed by six hours, about one in five truly positive results reverted to negative. A twelve-hour delay produced a similar reversion rate.³⁰ Delayed incubation also increased the rate of indeterminate results: no indeterminate results occurred with immediate incubation, but rates climbed to about 10% at six hours and 17% at twelve hours of delay.³¹

If you receive a surprising result, whether indeterminate, unexpectedly negative, or borderline, it is worth asking your provider whether the sample was processed promptly. Blood drawn late in the day at a site far from the processing lab is more susceptible to pre-analytical problems than a morning draw at a facility with an on-site incubator.

What Happens After a Positive Result

A positive QuantiFERON alone does not lead directly to TB treatment. The standard next step is a chest X-ray to look for signs of active disease. If the X-ray is normal and you have no symptoms like prolonged cough, fever, or weight loss, the working diagnosis is latent TB infection, which means TB bacteria are present but dormant. Your provider will then discuss preventive treatment, typically a course of antibiotics lasting three to four months, to reduce the risk of the infection becoming active later. In a prospective cohort of close TB contacts who were QFT-positive and received preventive therapy, none developed active TB.³²

Whether to treat a positive result depends on your risk profile. A healthcare worker in a low-incidence country with a low-positive borderline result and no known TB contact is in a very different situation from someone recently exposed to a household member with active TB who has a result of 8 IU/ml. The overall positive predictive value of the QuantiFERON for developing active TB was about 4% in one large contact study, but that rose to 17% among untreated contacts who were positive.³ These numbers mean that most people with a positive result will never get sick, but a sizable minority will, and preventive treatment dramatically lowers that risk.

Cost and Access Considerations

The QuantiFERON requires a single blood draw and no return visit, unlike the skin test, which needs two appointments. This is a genuine convenience advantage. On raw laboratory costs, the QuantiFERON is typically somewhat more expensive than the skin test. A Spanish study found the per-person costs were comparable once you factored in the time workers spent on two clinic visits for the skin test, with most of the skin test’s cost being eaten by participant time rather than supplies.³³ In BCG-vaccinated populations, however, the QuantiFERON’s greater specificity means fewer false positives, fewer unnecessary chest X-rays, and fewer courses of preventive treatment given to people who do not actually have TB. A cost-effectiveness analysis in U.S. healthcare workers found that IGRAs were both more effective and less costly than the skin test when all downstream consequences were accounted for.³⁴ A separate modeling study concluded that the QuantiFERON was more expensive with limited added benefit in certain screening scenarios, highlighting that the cost-effectiveness calculus depends heavily on the local TB prevalence and the proportion of workers who have been BCG-vaccinated.³⁵